SCHEMBL25044342

SCHEMBL25044342

Cc1cccc(F)c1-c1cc(NC2CN(C(=O)OC(C)(C)C)C2)c2ccncc2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 9/20 0.49
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
EHMT2 Q96KQ7 1/20 0.40
ABL1 P00519 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
ROCK2 O75116 1/20 0.38
CCR2 P41597 1/20 0.38
ROCK1 Q13464 1/20 0.38
PRKD2 Q9BZL6 5/20 0.38
KIT P10721 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
DYRK1A Q13627 1/20 0.37
USP30 Q70CQ3 1/20 0.37
BTK Q06187 1/20 0.37
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23301036 0.92 PRKCZ (0.50) PRKCZPIM1PIM2ROCK2CCR2
SCHEMBL29897364 0.92 PRKCZ (0.50) PRKCZPIM1PIM2ROCK2CCR2
SCHEMBL25043929 0.88 ABL1 (0.42) PRKCZPIM1PIM2EHMT2ABL1
SCHEMBL23301223 0.83 PRKCZ (0.58) PRKCZROCK2CCR2ROCK1PRKD2
SCHEMBL29897353 0.83 PRKCZ (0.58) PRKCZROCK2CCR2ROCK1PRKD2
SCHEMBL23328348 0.82 DYRK1A (0.46) PRKCZGPR119DYRK1ABTKEPHX2
SCHEMBL25043928 0.82 PIK3CD (0.44) PIM1PIM2ABL1HDAC1HDAC2
SCHEMBL25044178 0.82 PIK3CD (0.44) PIM1PIM2ABL1HDAC1HDAC2
SCHEMBL23301073 0.81 PRKCZ (0.54) PRKCZABL1ROCK2CCR2ROCK1
SCHEMBL23328190 0.80 USP30 (0.43) PRKCZPIM1PIM2ABL1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS SIK2, SIK3, SIK1 PRKCZ 875/4885PIM1 1089/4885PIM2 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.